Non-Hodgkin Lymphoma

Phase II trial with VELCADE and Rituximab begins

Published in Cancer Weekly, June 8th, 2004

Millennium Pharmaceuticals, Inc., (MLNM) announced the initiation of a multicenter phase II clinical trial of VELCADE (bortezomib) for Injection in combination with rituximab in patients with relapsed or refractory indolent (follicular and marginal zone) non-Hodgkin lymphoma.

The randomized study will assess efficacy, overall safety, and tolerability of the combination in two different dosing schedules. VELCADE is also being investigated in a range of phase I and II solid and hematologic tumors. It is currently approved in the United States for the treatment of patients with relapsed and refractory multiple myeloma and is also approved in Europe for the same...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry